作为癌症特异性生物标志物来源的核结构
Nuclear structure as a source of cancer specific biomarkers.
作者信息
Leman Eddy S, Getzenberg Robert H
机构信息
The Johns Hopkins University School of Medicine, Department of Urology, 600 N. Wolfe Street, Marburg 121, Baltimore, Maryland 21287, USA.
出版信息
J Cell Biochem. 2008 Aug 15;104(6):1988-93. doi: 10.1002/jcb.21363.
Abstract
There are few biomarkers that have been developed which have proven clinical utility for the detection and prognosis of cancer. Cancer is diagnosed today, in large part, by examining cells under the microscope and determining the shape and texture of the nucleus. The molecular underpinnings of this hallmark of cancer are the components of the nuclear matrix. Utilizing proteomics focused on this subset of proteins, biomarkers have been identified that are specific for cancer types including prostate, colon and bladder cancer. These cancer biomarkers now serve as the basis of assays which can specifically identify individuals with cancer by sampling their blood and/or urine. In addition, these may serve as potential therapeutic targeting or imaging approaches.
摘要
目前已开发出的生物标志物中，很少有已被证明对癌症检测和预后具有临床实用性的。如今，癌症的诊断在很大程度上是通过在显微镜下检查细胞并确定细胞核的形状和质地来进行的。癌症这一标志的分子基础是核基质的组成部分。利用专注于这一蛋白质子集的蛋白质组学，已鉴定出对包括前列腺癌、结肠癌和膀胱癌在内的癌症类型具有特异性的生物标志物。这些癌症生物标志物现在是检测方法的基础，这些检测方法可以通过采集血液和/或尿液样本专门识别患有癌症的个体。此外，这些生物标志物还可作为潜在的治疗靶点或成像方法。
相似文献
1
Nuclear structure as a source of cancer specific biomarkers.作为癌症特异性生物标志物来源的核结构
J Cell Biochem. 2008 Aug 15;104(6):1988-93. doi: 10.1002/jcb.21363.
2
Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.通过外显子阵列分析鉴定结肠、膀胱和前列腺癌中的可变剪接。
Mol Cell Proteomics. 2008 Jul;7(7):1214-24. doi: 10.1074/mcp.M700590-MCP200. Epub 2008 Mar 18.
3
Urine cytology of primary and secondary urinary bladder adenocarcinoma.原发性和继发性膀胱腺癌的尿液细胞学检查
Cancer. 1998 Dec 25;84(6):335-43.
4
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.泌尿生殖系统肿瘤侵袭性的生物标志物，重点是肾、膀胱和前列腺癌。
Expert Rev Mol Diagn. 2018 Jul;18(7):645-655. doi: 10.1080/14737159.2018.1490179. Epub 2018 Jun 29.
5
Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients.在大量乳腺癌、前列腺癌、结肠癌和膀胱癌患者中定义循环肿瘤细胞的维度。
Mol Oncol. 2021 Jan;15(1):116-125. doi: 10.1002/1878-0261.12802. Epub 2020 Oct 4.
6
Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.核p53在膀胱癌、前列腺癌和肾癌中的过表达。
Int J Urol. 1997 Nov;4(6):546-51. doi: 10.1111/j.1442-2042.1997.tb00306.x.
7
Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.尿细胞外囊泡中的蛋白质谱是恶性肿瘤的标志物，且与膀胱癌的肌肉浸润性相关。
Cancer Lett. 2025 Jan 28;609:217352. doi: 10.1016/j.canlet.2024.217352. Epub 2024 Nov 23.
8
Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation.LINE-1编码的ORF2蛋白在结肠和前列腺转化早期的表达增强。
Oncotarget. 2016 Jan 26;7(4):4048-61. doi: 10.18632/oncotarget.6767.
9
Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer.
Urol Clin North Am. 2000 Feb;27(1):47-51, viii. doi: 10.1016/s0094-0143(05)70233-0.
10
Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.综合免疫组化和分子分析可提高前列腺癌放疗后膀胱癌高级别癌的诊断率。
Mod Pathol. 2020 Sep;33(9):1802-1810. doi: 10.1038/s41379-020-0543-y. Epub 2020 Apr 20.
引用本文的文献
1
Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion.胶质母细胞瘤中转录调控蛋白的改变和 YBX1 作为肿瘤侵袭的潜在调节剂。
Sci Rep. 2019 Jul 29;9(1):10986. doi: 10.1038/s41598-019-47360-9.
2
Advances in the computational and molecular understanding of the prostate cancer cell nucleus.前列腺癌细胞核的计算和分子理解的进展。
J Cell Biochem. 2018 Sep;119(9):7127-7142. doi: 10.1002/jcb.27156. Epub 2018 Jun 20.
3
Limb-bud and Heart Overexpression Inhibits the Proliferation and Migration of PC3M Cells.肢体芽和心脏过表达抑制PC3M细胞的增殖和迁移。
J Cancer. 2018 Jan 1;9(2):424-432. doi: 10.7150/jca.21375. eCollection 2018.
4
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.miR-212失调通过hnRNPH1介导的AR和AR-V7调控促进去势抵抗：对前列腺癌种族差异的影响
Clin Cancer Res. 2016 Apr 1;22(7):1744-56. doi: 10.1158/1078-0432.CCR-15-1606. Epub 2015 Nov 9.
5
Association of serum EPCA-2 level with prostate cancer in Chinese Han population.中国汉族人群血清EPCA-2水平与前列腺癌的关联
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9397-403. eCollection 2015.
6
Condensins are Required for Maintenance of Nuclear Architecture.凝缩蛋白是维持核结构所必需的。
Cells. 2014 Aug 22;3(3):865-82. doi: 10.3390/cells3030865.
7
Characterization of biological responses of colorectal cancer cells to anticancer regimens.结直肠癌细胞对抗癌治疗方案的生物学反应特征
J Korean Surg Soc. 2012 Jul;83(1):21-9. doi: 10.4174/jkss.2012.83.1.21. Epub 2012 Jun 26.
8
Prognostic value of nuclear matrix protein expression in localized prostate cancer.核基质蛋白表达在局限性前列腺癌中的预后价值。
J Cancer Res Clin Oncol. 2012 Aug;138(8):1379-84. doi: 10.1007/s00432-012-1216-0. Epub 2012 Apr 10.
9
Potential of soluble CD26 as a serum marker for colorectal cancer detection.可溶性CD26作为结直肠癌检测血清标志物的潜力。
World J Clin Oncol. 2011 Jun 10;2(6):245-61. doi: 10.5306/wjco.v2.i6.245.
10
Role of nuclear architecture in epigenetic alterations in cancer.核架构在癌症表观遗传改变中的作用。
Cold Spring Harb Symp Quant Biol. 2010;75:507-15. doi: 10.1101/sqb.2010.75.031. Epub 2011 Mar 29.
本文引用的文献
1
Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
Cancer Res. 2007 Jun 15;67(12):5600-5. doi: 10.1158/0008-5472.CAN-07-0649.
2
Characterization of nuclear matrix protein alterations associated with renal cell carcinoma.
Urology. 2007 Jun;69(6):1227-30. doi: 10.1016/j.urology.2007.02.053.
3
EPCA-2: a highly specific serum marker for prostate cancer.EPCA-2：一种用于前列腺癌的高度特异性血清标志物。
Urology. 2007 Apr;69(4):714-20. doi: 10.1016/j.urology.2007.01.097.
4
Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma.
Urology. 2006 Apr;67(4):848-50. doi: 10.1016/j.urology.2005.10.029. Epub 2006 Mar 29.
5
Cancer statistics, 2006.2006年癌症统计数据。
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. doi: 10.3322/canjclin.56.2.106.
6
Highly specific urine-based marker of bladder cancer.膀胱癌高度特异性的尿液标志物。
Urology. 2005 Dec;66(6):1256-60. doi: 10.1016/j.urology.2005.07.010.
7
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.前列腺癌中TMPRSS2与ETS转录因子基因的反复融合
Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679.
8
Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.BLCA-4在膀胱癌病理生物学中作用的机制分析。
Cancer Res. 2005 Aug 15;65(16):7145-50. doi: 10.1158/0008-5472.CAN-05-1142.
9
Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.一种新型生物标志物EPCA在前列腺腺癌及癌前病变中的表达
J Urol. 2005 Aug;174(2):514-8. doi: 10.1097/01.ju.0000165154.41159.b1.
10
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.初始前列腺特异性抗原（PSA）水平为3.0 ng/ml或更低的男性中前列腺特异性抗原的操作特征
JAMA. 2005 Jul 6;294(1):66-70. doi: 10.1001/jama.294.1.66.
Zotero 插件